Collaborations & Alliances

ProBioGen, LAVA to Develop Cell Lines for Bispecific Candidate

ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen and LAVA Therapeutics N.V. entered a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA’s pipeline.   ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform, including its DirectedLuck Transposase technology for the generation of stable high-titer cell lines   “We are delighted to continue our collaboration with LAVA to develop cell lines for another...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters